Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / NVS - Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? | Benzinga

NVS - Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? | Benzinga

Novartis AG

Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS).

The Wall Street Journal noted that Novartis is nearing the final stages of acquiring Cytokinetics, a company focused on developing heart disease drugs. 

This move aligns with the trend of pharmaceutical companies acquiring rapidly growing biotechs to enhance their product pipelines. 

Also Read: Full story available on Benzinga.com
Stock Information
Company Name: Novartis AG
Stock Symbol: NVS
Market: NYSE
Website: novartis.com
Menu
NVS NVS Quote NVS Short NVS News NVS Articles NVS Message Board
Get NVS Alerts

News, Short Squeeze, Breakout and More Instantly...